Novo Nordisk is trading 6.23% down at DKK 264.00, with no confirmed September 21, 2026 company announcement directly explaining the decline.
- Investors are focused on the Capital Markets Day and concerns about competition from Eli Lilly, semaglutide patent expiries, pricing pressure, and Novo’s thin late-stage pipeline.
- Reuters reported that analysts want clearer medium-term targets and a strategy beyond Wegovy and Ozempic, but did not explicitly link those concerns to the same-day move.